harpoontx.com (HARP): Price-to-Projected Revenue Ratio

HARP (Harpoon Therapeutics Inc) - company brandmark

Harpoon Therapeutics (HARP) is developing targeted oncology therapies via the TriTAC system, leveraging support from major pharmaceutical partners and strict temperature control during drug delivery. The projected P/S value on the GURU.Markets chart reflects liquidity dynamics, where the current figure stands at 13.20. A flawless image and institutional trust have been established for the brand following its merger with an industry behemoth.

HARP Harpoon Therapeutics Inc: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 03/16/2024

Analytical breakdowns for Harpoon Therapeutics Corp (HARP)

- stock price and consensus target price:
Stock Quotes Harpoon Therapeutics, Inc.|HARP - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value Harpoon Therapeutics Corp|HARP - Business Value
- book value of equity indicators:
Net Assets per Single Share Harpoon Therapeutics|HARP - Total Stockholders' Equity|Market Cap to Net Assets Ratio harpoontx.com|HARP - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Harpoon Therapeutics|HARP - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Harpoon Therapeutics|HARP - Aggregate Debt Obligations|Debts to Book Capitalization Harpoon Therapeutics Corp|HARP - Long-Term Debt|Company Short-Term Debt Harpoon Therapeutics|Quick Ratio harpoontx.com
- business earnings and investment ratios data:
HARP - Net Profit|Expected Profit Harpoon Therapeutics|HARP - Market Cap to Net Income|Projected Price to Earnings Harpoon Tx|HARP - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Harpoon Therapeutics Corp|HARP - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Harpoon Therapeutics|HARP - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months harpoontx.com|HARP - Earnings per share increase in current year|Net earnings per share growth forecast for next year Harpoon Therapeutics
- revenue and sales details:
HARP - Company Annual Revenue|Company Projected Revenue Harpoon Therapeutics, Inc.|HARP - Price to Sales|Price-to-Projected Revenue Ratio Harpoon Therapeutics Corp
Summary company analysis:Harpoon Therapeutics, Inc. HARP
Manufactured products of Harpoon Therapeutics Corp

Amid high uncertainty surrounding immuno-oncology clinical trials and a liquidity crunch, Harpoon Therapeutics (HARP) is critically dependent on market expectations for future sales. The ratio of projected market capitalization to expected revenue measures the premium investors are willing to pay for the potential success of the drugs, allowing forward EV/Revenue to distinguish fundamental revaluation from speculative hype.

Competitor analysis

ImmunityBio - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Holdings IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (Arcus Corp) - Market Cap to Projected Revenue|Zymeworks Inc. (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio tangotx.com (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune Group, Inc.)|Forward Price to Sales LYEL|Innate Pharma - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology, Inc.|cgen.com (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech Inc. - Forward Price to Sales|STRO (Sutro Biopharma, Inc.) - Forward P/S Multiple|Forward P/S Multiple minktherapeutics.com|Price-to-Projected Revenue Ratio Werewolf Therapeutics (HOWL)|IMMX: Future Price to Revenue|ALX Oncology Holdings - Forward Price-to-Revenue Multiple|cuebiopharma.com (CUE) - Market Cap to Future Revenue Ratio|PDS Biotechnology Corp - Forward P/S Multiple|Forward Price to Sales SONN (Sonnet BioTherapeutics)|MAIA: Forward P/S Multiple|Liminatus Pharma Inc. (LIMN) - Forward P/S Multiple|Price-to-Projected Revenue Ratio LAVA Therapeutics NV|NXTC: Forward Price to Sales|Price-to-Projected Revenue Ratio Leap Therapeutics, Inc. (LPTX)|INTS: Future Price to Revenue|Price-to-Projected Revenue Ratio Sensei Biotherapeutics, Inc. SNSE|Theriva Biologics Inc (TOVX) - Market Cap to Future Revenue Ratio|GRTS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Kineta Corp|NexImmune, Inc. (NEXI) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TSBX|Forward Price-to-Revenue Multiple VCNX